ASX Announcement CEO’s Letter to Shareholders Brisbane, Australia, 20 November 2026 – Ceretas Limited (ASX:CTS) (“Ceretas” or “the Company”), an Australian medical technology company developing a portable, non-invasive therapeutic ultrasound platform to treat Alzheimer’s disease and...
AGM - CEO's Letter to Shareholders
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Ceretas Ltd has released a letter from the CEO to shareholders ahead of its Annual General Meeting, highlighting significant progress since its IPO earlier this year. Additionally, the CEO emphasizes the company's strong financial position and ongoing development of its therapeutic ultrasound technology.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Earlier from Ceretas
- Phase 2 CERE-CALM trial expands into Victoria
- Quarterly Activities/Appendix 4C Cash Flow Report
- First Patient Enrolled in Phase 2 CERE-CALM Clinical Trial
- Notice of Annual General Meeting/Proxy Form
- Investor Presentation - October 2026
Later from Ceretas
All Ceretas news releasesFollow Ceretas into a list and get an email when it puts out news.
Follow Ceretas